IP Library Granted Patent US 8,598,197
Granted Patent B2
US 8,598,197 · App. 13/869,576 · Granted Dec 3, 2013

CDK inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,197
App. No.
13/869,576
Granted
Dec 3, 2013
Kind
B2
Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Claims (95)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

Z is —(CH 2 ) x — wherein x is 1, 2, 3 or 4 or —O—(CH 2 ) z — wherein z is 2, 3 or 4;

each X is independently CH or N;

each of R and R 8 are independently H, C 1 -C 3 alkyl or haloalkyl;

each R 1 is independently aryl, alkyl, cycloalkyl or haloalkyl, wherein each of said alkyl, cycloalkyl and haloalkyl groups optionally includes O or N heteroatoms in place of a carbon in the chain and two R 1 's on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

y is 0, 1, 2, 3 or 4;

R 2 is -(alkylene) m -heterocyclo, -(alkylene) m -heteroaryl, -(alkylene) m -NR 3 R 4 , -(alkylene) m -C(O)—NR 3 R 4 ; -(alkylene) m -C(O)—O-alkyl; -(alkylene) m -O—R 5 , -(alkylene) m -S(O) n —R 5 , or -(alkylene) m -S(O) n —NR 3 R 4 any of which may be optionally independently substituted with one or more R x groups as allowed by valance, and wherein two R x groups bound to the same or adjacent atom may optionally combine to form a ring and wherein m is 0 or 1 and n is 0, 1 or 2;

R 3 and R 4 at each occurrence are independently:

(i) hydrogen or

(ii) alkyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, or heteroarylalkyl any of which may be optionally independently substituted with one or more R x groups as allowed by valance, and wherein two R x groups bound to the same or adjacent atom may optionally combine to form a ring; or R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form a heterocyclo ring optionally independently substituted with one or more R x groups as allowed by valance, and wherein two R x groups bound to the same or adjacent atom may optionally combine to form a ring;

R 5 and R 5 * at each occurrence is:

(i) hydrogen or

(ii) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, or heteroarylalkyl any of which may be optionally independently substituted with one or more R x groups as allowed by valance;

R x at each occurrence is independently, halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, -(alkylene) m -OR 5 , -(alkylene) m -O-alkylene-OR 5 , -(alkylene) m -S(O) n —R 5 , -(alkylene) m -NR 3 R 4 , -(alkylene) m -CN, -(alkylene) m -C(O)—R 5 , -(alkylene) m -C(S)—R 5 , -(alkylene) m -C(O)—OR 5 , -(alkylene) m -O—C(O)—R 5 , -(alkylene) m -C(S)—OR 5 , -(alkylene) m -C(O)-(alkylene) m -NR 3 R 4 , -(alkylene) m -C(S)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(S)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—R 5 , -(alkylene) m -N(R 3 )—C(S)—R 5 , -(alkylene) m -O—C(O)—NR 3 R 4 , -(alkylene) m -O—C(S)—NR 3 R 4 , -(alkylene) m -SO 2 —NR 3 R 4 , -(alkylene) m -N(R 3 )—SO 2 —R 5 , -(alkylene) m -N(R 3 )—SO 2 —NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—OR 5 )-(alkylene) m -N(R 3 )—C(S)—OR 5 , or -(alkylene) m -N(R 3 )—SO 2 —R 5 ; wherein:

said alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl groups may be further independently substituted with one or more -(alkylene) m -CN, -(alkylene) m -OR 5 *, -(alkylene) m -S(O) n —R 5 *, -(alkylene) m -NR 3 *R 4 *, -(alkylene) m -C(O)—R 5 *, -(alkylene) m -C(═S)R 5 *, -(alkylene) m -C(═O)OR 5 *, -(alkylene) m -OC(═O)R 5 *, -(alkylene) m -C(S)—OR 5 *, -(alkylene) m -C(O)—NR 3 *R 4 *, -(alkylene) m -C(S)—NR 3 *R 4 *, -(alkylene) m -N(R 3 *)—C(O)—NR 3 *R 4 *, -(alkylene) m -N(R 3 *)—C(S)—NR 3 *R 4 *, (alkylene) m -N(R 3 *)—C(O)—R 5 *, -(alkylene) m -N(R 3 *)—C(S)—R 5 *, -(alkylene) m -O—C(O)—NR 3 *R 4 *, -(alkylene) m -O—C(S)—NR 3 *R 4 *, -(alkylene) m -SO 2 —NR 3 *R 4 *, -(alkylene) m -N(R 3 *)—SO 2 —R 5 *, -(alkylene) m -N(R 3 *)—SO 2 —NR 3 *R 4 *, -(alkylene) m -N(R 3 *)—C(O)—OR 5 *, -(alkylene) m -N(R 3 *)—C(S)—OR 5 *, or -(alkylene) m -N(R 3 *)—SO 2 —R 5 *,

n is 0, 1 or 2, and

m is 0 or 1; and

R 3 * and R 4 * at each occurrence are independently:

(i) hydrogen or

(ii) alkyl, alkenyl, alkynyl cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, or heteroarylalkyl any of which may be optionally independently substituted with one or more R x groups as allowed by valance; or R 3 * and R 4 * together with the nitrogen atom to which they are attached may combine to form a heterocyclo ring optionally independently substituted with one or more Rx groups as allowed by valance, and

R 6 is a lower alkyl or absent.

2. The compound of claim 1 , wherein R 8 is hydrogen or C 1 -C 3 alkyl.

3. The compound of claim 1 having the formula selected from the structures shown in FIG. 4 .

4. The compound of claim 1 having formula:

5. The compound of claim 1 having formula:

6. The compound of claim 1 having formula:

7. The compound of claim 1 having formula:

8. The compound of claim 1 having formula:

9. The compound of claim 1 having formula:

10. The compound of claim 1 having formula:

11. The compound of claim 1 having formula:

12. The compound of claim 1 having formula:

13. The compound of claim 1 having formula:

14. The compound of claim 1 , wherein both of X are N.

15. The compound of claim 1 , wherein R 2 is selected from the structures of FIG. 1 .

16. The compound of claim 1 , wherein R 2 is -(alkylene) m -heterocyclo, -(alkylene) m -NR 3 R 4 , -(alkylene) m -C(O)—NR 3 R 4 , -(alkylene) m -C(O)—O-alkyl or -(alkylene) m -OR 5 any of which may be optionally independently substituted with one or more R x groups as allowed by valance, and wherein two R x groups bound to the same or adjacent atom may optionally combine to form a ring.

17. The compound of claim 1 , wherein R 2 is

wherein:

R 2 * is a bond, alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1;

P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;

each R x1 is independently -(alkylene) m -(C(O)) m -(alkylene) m -(N(R N )) m -(alkyl) m wherein each m is independently 0 or 1 provided at least one m is 1, —(C(O))—O-alkyl, -(alkylene) m -cycloalkyl wherein m is 0 or 1, —N(R N )-cycloalkyl, —C(O)-cycloalkyl, -(alkylene) m -heterocyclyl wherein m is 0 or 1, or —N(R N )-heterocyclyl, —C(O)-heterocyclyl, —S(O) 2 -(alkylene) m wherein:

R N is H, C 1 to C 4 alkyl or C 1 to C 6 heteroalkyl, and

wherein two R x1 can, together with the atoms to which they attach on P, which may be the same atom, form a ring; and

t is 0, 1 or 2.

18. The compound of claim 17 , wherein R 2 is

wherein P* is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group and R 2 *, R x1 and t are as previously defined.

19. The compound of claim 17 , wherein R 2 is

20. The compound of claim 18 , wherein R 2 is

21. The compound of claim 17 , wherein each R x1 is only optionally substituted by C 1 -C 4 alkyl, halogen or hydroxy.

22. The compound of claim 18 , wherein each R x1 is only optionally substituted by C 1 -C 4 alkyl, halogen or hydroxy.

23. The compound of claim 19 , wherein each R x1 is only optionally substituted by C 1 -C 4 alkyl, halogen or hydroxy.

24. The compound of claim 20 , wherein each R x1 is only optionally substituted by C 1 -C 4 alkyl, halogen or hydroxy.

25. The compound of claim 1 , wherein R 2 is

wherein:

R 2 * is a bond, alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O)-2-(alkylene) m or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1;

P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;

P1 is a 4- to 6-membered monocyclic saturated heterocyclyl group;

each R x2 is independently hydrogen or alkyl; and

s is 0, 1 or 2.

26. The compound of claim 25 , wherein R 2 is

27. The compound of claim 1 , wherein R x is not further substituted.

28. The compound of claim 17 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m - , -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

29. The compound of claim 18 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m - , -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkyleneis not further substituted.

30. The compound of claim 19 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

31. The compound of claim 20 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

32. The compound of claim 21 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

33. The compound of claim 22 wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

34. The compound of claim 23 wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

35. The compound of claim 24 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

36. The compound of claim 25 , wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

37. The compound of claim 26 wherein R 2 * is alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O)2-(alkylene) m - and or -(alkylene) m -NH-(alkylene) m - wherein each m is independently 0 or 1, and wherein any alkylene is not further substituted.

38. The compound of claim 1 , wherein R is hydrogen or C 1 -C 3 alkyl.

39. The compound of claim 16 , wherein the alkylene in R 2 is methylene.

40. The compound of claim 17 , wherein the alkylene in R 2 is methylene.

41. The compound of claim 25 , wherein the alkylene in R 2 is methylene.

42. The compound of claim 1 , wherein R 2 is -(alkylene) m -heterocyclo or -(alkylene) m -heteroaryl,

R is hydrogen, and,

X is independently CH or N.

43. The compound of claim 42 , wherein R 2 is -(alkylene) m -heterocyclo.

44. The compound of claim 42 , wherein m is 0.

45. The compound of claim 43 , wherein m is 0.

46. The compound of claim 42 , wherein m is 1.

47. The compound of claim 43 , wherein m is 1.

48. The compound of claim 42 , wherein the heterocyclo is not substituted.

49. The compound of claim 43 , wherein the heterocyclo is not substituted.

50. The compound of claim 42 , wherein R 2 is

51. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1 having the formula selected from the structures shown in FIG. 5 .

53. The compound of claim 1 having the formula selected from the structures shown in FIG. 6 .

54. The compound of claim 1 having the formula selected from the structures shown in FIG. 7 .

55. The compound of claim 1 having the formula selected from the structures shown in FIG. 8 , wherein the selected structure falls within claim 1 .

56. The compound of claim 1 , wherein R 2 is selected from the structures of FIG. 2 .

57. The compound of claim 1 , wherein R 2 is selected from the structures of FIG. 3 .

58. The compound of claim 1 , wherein R 6 is absent.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 071018/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 071018/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069371/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069371/0832 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055746/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: STRUM, JAY C.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0743 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0678 →